Companies · Insurance
New York · NY, USA; Cambridge, MA, USA · Insurance · founded 2019 · https://www.givelegacy.com
Diligence memoA one-page analyst read on Legacy — recommendation, valuation, rhythm, risks.→Legacy: limited disclosed financing to assess.
Synthesized from the figures below est. — every claim rests on a number shown on this page.
Legacy is one of 146 Insurance companies tracked from New York, NY, USA; Cambridge, MA, USA, on record since 2019. By capital raised it ranks mid-pack (ahead of 68% of sector peers), and mid-pack by modeled valuation est..
Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.
AI analyst read est. — model-extracted from this company's public description, not a verified fact. 30%
operates a technology-led product inferred from public copy
Grounded in: “You are a venture analyst”
Legacy helps you test, improve, and freeze your sperm
**TL;DR:** Legacy (YC S19) is a startup focused on the fast-growing field of fertility and family planning. Founded at Harvard, the company has now raised $40M from leading investors like FirstMark Capital, Bain Capital Ventures, Section 32, Tribe Capital, and even celebrities like Justin Bieber, The Weeknd, and others. **What we're doing** We aim to change the outdated view that fertility is a "women's issue" by creating an accessible, affordable product for men & people with sperm. This includes everything from a mail-in kit for sperm testing & sperm freezing, personalized sperm improvement products, tele-health, DNA fragmentation analysis, supplements, and more. **Why are we the leader?** The company was founded at Harvard by a team of healthcare and fertility experts. We obsess about talent density and have out-executed our competitors over the past few years. Beyond our D2C channel, we've also unlocked: 1. Nationwide insurance coverage (10M+ lives) 2. Military contracts (Including the Navy SEALs and 15M+ veterans) 3. Employer offerings (Working with the top fertility benefit providers) **Tell me about the team** We're a team of about 30, extremely diverse (majority female, majority immigrants, strong LGBQTIA+ representation, age range of 25-65), and very values driven. Our 5 values are customer centricity, reliability, kindness, openness, and winning. Learn more about our values here: https://khaled-legacy.medium.com/legacys-values-and-why-they-matter-db116539d3da Learn more about our workplace here: https://khaled-legacy.medium.com/how-and-why-legacy-is-reinventing-workplace-benefits-9e5fda6cb863 Read about our mission to humanize the path to parenthood: https://khaled-legacy.medium.com/how-and-why-legacy-is-reinventing-workplace-benefits-9e5fda6cb863 Learn more about sperm and why it matters here: docsend.com/view/zkgk7ws
As reported in public records reported — not modeled.
Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.
No round amounts on record to chart.
No staged rounds to sequence.
Round size and date are reported; the stage label is inferred from round size. Valuation is modeled from stage benchmarks. Directional, not a quoted figure.
Not enough modeled valuation points to chart a trajectory.
Benchmarked against 146 companies in Insurance. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.
Raised more than 68% of sector peers (real $). Modeled value above 68% of peers (estimate).
Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.
| Stage | Amount · real | Announced | Post-money · est | Value · est | Conf. |
|---|---|---|---|---|---|
| No rounds recorded. | |||||
Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.
Legacy is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.
Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.
| Company | Sector | Stage | Raised · real | Value · est | Why similar |
|---|---|---|---|---|---|
| Acadia Fire Insurance Company | Insurance | — | — | — | same sector |
| Acolite | Insurance | — | — | — | same sector |
| Adaptional | Insurance | — | — | — | same sector |
| Aegis | Insurance | — | — | — | same sector |
| AI Insurance | Insurance | — | — | — | same sector |
| Air Centurion Insurance Services, Inc. | Insurance | Pre-Seed | $600K | $13.9M | same sector |
| Albiware Inc. | Insurance | — | — | — | same sector |
| Altrina | Insurance | — | — | — | same sector |
Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.
| Company | Sector | Stage | Value · est | Match |
|---|---|---|---|---|
| Modern Fertility At-home fertility test for women who aren't ready for kids right now… | — | — | — | 78% |
| Legacy Ventures, LLC | Biotechnology | Series A | $58.2M | 76% |
| Mate Fertility, Inc. | Other Technology | Seed | $38.7M | 73% |
| Play Health Perimenopause Care Platform | Biotech | — | — | 73% |
| Circle Medical Modern primary care via video and in-person | Healthtech | — | — | 72% |
| YourChoice Therapeutics YourChoice therapeutics is revolutionizing the contraceptive market… | Biotech | — | — | 72% |
| twoplus fertility An effective home-use fertility treatment for natural conception | — | — | — | 71% |
| Fertility Partners Holdings Inc. | Other Health Care | Pre-Seed | $3.3M | 71% |
See where Legacy sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.
If you work at Legacy, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.
Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.